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OBJECTIVE: To determine the prevailing levels of rubella immunity among school-aged children who received a single
dose of measles-mumps-rubella (MMR) vaccine at one year of age.
DESIGN: Cross-sectional study with a two stage cluster sampling of randomly picked schools across the province of
Newfoundland.
STUDY POPULATION AND METHODS: A total of 1053, five to 17-year-old children were enrolled; vaccination history
was verified through official records; and a sample of blood was taken. Rubella immunity was determined by enzyme
immunoassay based on a serum antibody protective cut-off titre of more than 10 IU.
RESULTS: A total of 145 (13.8%) were found to be nonimmune. The rate of susceptibility ranged from 3.2% to 25.9%
for different age groups. The proportion susceptible was significantly higher at 16.5% in the age group eight to 17 years
old versus 3.9% for the age group five to eight years old (χ2=24.08; df=1, P<0.001). There was a significant regression
of logarithm titre values on the age of children with an average decline in titre values of 8.1% per annum.
CONCLUSIONS: A substantial number of those who were given a single dose of MMR II vaccine may not have protective
immunity against rubella as they reach prime reproductive age. There is a definite need to consider a two-dose rubella
vaccination strategy in Canada, and these data suggest the second dose given after eight years of age will be most
beneficial. In the move towards a routine two-dose measles vaccination strategy in Canada, the MMR II vaccine is being
used for the second dose and given either at 18 months of age or at school entry. While this approach will have an
overall beneficial effect, the impact of the above timing of the second dose on long term rubella immunity cannot be
predicted at this time. These data also underscore the continuing need for prenatal rubella screening program.
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Taux d’anticorps antirubéole chez les enfants d’âge scolaire à Terre-Neuve : implications
d’une stratégie de vaccination à deux doses
OBJECTIF : Déterminer les taux d’immunité contre la rubéole qui prévalent chez les enfants d’âge scolaire qui ont reçu
une seule dose de vaccin ROR à l’âge d’un an.
voir page suivante
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There is renewed interest and resolve to eliminate indige-nous measles and to control and eliminate indigenous
rubella infection during pregnancy (1-3). Because measles,
with its high infective potential and continuing outbreaks es-
pecially among previously vaccinated populations (4-6), at-
tracts the major emphasis, a two-dose measles immunization
strategy has gained support in recent years (2,7). While there
are recent epidemiological and laboratory data to support a
two-dose strategy for the control and elimination of measles
(3,8-10), there are insufficient data on the prevailing levels of
immunity against rubella (1). It is well known that vaccine-in-
duced immunity is lower than that resulting from natural
exposure to the wild virus, and there are indications that
vaccine-induced rubella immunity declines over time among
those who received a single dose of measles-mumps-rubella
(MMR) vaccine (11,12). Because many of the current cohort of
women of childbearing age have not been exposed to the wild
rubella virus, the question concerning the level of protection
against rubella infection among women of childbearing age has
become an important and timely issue of public health signifi-
cance (1). An increase in the incidence of rubella has been
recognized in the United States (13), and congenital rubella
continues to occur in both Canada and the United States (14,15).
A recent Canadian consensus conference on rubella has set
the goal to eliminate indigenous rubella infection during preg-
nancy by the year 2000 (1), coinciding with the goal to elimi-
nate indigenous measles in North America (16). In an effort to
achieve this goal, many provinces in Canada are now in the
process of implementing a routine two-dose vaccination strat-
egy that includes both measles and rubella (17). In addition,
some provinces that are implementing a catch-up program
have chosen to use a monovalent measles vaccine for this
purpose (17). In the above context, a precise knowledge of the
levels of rubella immunity in previously vaccinated school-
aged children would be useful in the overall consideration of
whether to use both measles and rubella antigens in the
two-dose strategy, the timing of the second dose and the
rationale for continuing prenatal rubella screening program.
In view of this, we carried out a cross sectional study of
children from five to 17 years of age to obtain Canadian data
on the prevailing levels of immunity against rubella among
those who received a single dose of MMR II vaccine (Merck
Sharp & Dome, Pennsylvania) at one year of age.
PATIENTS AND METHODS
Study population: The study population comprised children
in kindergarten to grade nine from five to 17 years of age. To
obtain a provincial representation, children were enrolled
through random selection of schools across the province of
Newfoundland. A two-stage cluster sampling was done in each
of five health regions. Three schools were picked at random in
each health region, and up to four classes within each grade
in a school were approached to enroll volunteers. (Random
numbers were generated from the statistical software Minitab
for Windows version 9 [Minitab, Pennsylvania]). Informed
consent was obtained from all volunteers and their parents,
and a sample of blood was obtained by venipuncture. MMR
vaccination history was verified for all study subjects through
official records maintained by the respective regional public
health officials. (Childhood immunizations are mostly pro-
vided by public health services, and where physicians offer this
service, the records are passed on to the public health registry).
Test results were sent to all participants and the concerned
public health units, and the children testing nonimmune were
offered a second dose of MMR vaccine. This study was ap-
proved by the Human Investigation Committee, Faculty of
Medicine, Memorial University of Newfoundland, St John’s,
Newfoundland.
Laboratory methods: Serum samples were stored at –70°C
until ready for testing for rubella antibodies. Rubella antibody
was detected by Axsym Rubella IgG (Abbott laboratories, Illi-
nois), a commercial quantitative enzyme immunoassay, and
done in accordance with the manufacturer’s instructions. A
reading of greater than 10 IU was considered to indicate
protective immunity (18).
Statistical analyses: The estimated sample size was 1047.
This sample size was adequate to detect a decline in titre of 4%
per annum with equal number of children for all the ages from
5 to 17 years, at 5% level of significance and with 90% power.
Regression analysis was used to study the relation between
MODÈLE : Étude transversale avec échantillonnage en grappe à deux phases provenant d’écoles choisies au hasard à
Terre-Neuve.
POPULATION ÉTUDIÉE ET MÉTHODES : En tout, 1 053 enfants de 5 à 17 ans ont été inscrits. Le carnet de vaccination
a été vérifié au moyen des dossiers officiels et un prélèvement sanguin a été effectué. L’immunité contre la rubéole a
été déterminée au moyen d’un immunodosage enzymatique sur la base des titres protecteurs seuils d’anticorps sériques
de plus de 10 UI.
RÉSULTATS : En tout, 145 (13,8 %) individus se sont révélés non protégés. Le taux de sensibilité allait de 3,2 % à 25,9
% pour les différents groupes d’âge. Le taux de sujets sensibles était nettement plus élevé (16,5 %) chez les 8 à 17 ans
que (3,9 %) chez les 5 à 8 ans (χ2 = 24,08; df = 1, P < 0.001). On a noté une régression significative des titres
logarithmiques d’après l’âge des enfants, avec un déclin moyen des titres de 8,1 % par an.
CONCLUSIONS : Un nombre substantiel d’individus ayant reçu une seule dose de ROR II ne seraient peut-être pas
protégés contre la rubéole lorsqu’ils arrivent à l’adolescence. Il faut envisager une stratégie de vaccination à deux doses
contre la rubéole au Canada et ces données suggèrent que la deuxième dose soit administrée après l’âge de 8 ans pour
être le plus efficace. Selon la tendance d’administrer une vaccination à deux doses contre la rougeole de routine au
Canada, le vaccin ROR II est utilisé en deuxième dose et administré soit à l’âge de 18 mois ou au moment d’entrer à
l’école. Cette approche aura un effet global bienfaisant, mais l’impact de cette synchronisation de la deuxième dose sur
l’immunité à long terme contre la rubéole ne peut être prévisible pour l’instant. Ces données soulignent également la
nécessité d’un programme de dépistage prénatal de la rubéole.
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the titre levels and age of the children. χ2 test was used to study
the association between protection level and each of the fac-
tors, age and sex.
RESULTS
Blood samples were available for testing from 1053 (543
males and 510 females; median age 10.5 years) of 1075
children enrolled. The number of children in each yearly cohort
ranged from 89 to 148 for the age groups 6 to 14 years and
was 47 for the five-year-olds and 27 for the 15- to 17-year-
olds. All had received a single dose of MMR II vaccine at one
year of age. Of the 1053 children, 15 (1.4%) had no detectable
rubella antibody titres (less than 1 IU), and an additional 130
(12.3%) had titres between 1 and 10 IU. Therefore, based on
the protective cut-off titre of 10 IU, a total of 145 (13.8%)
children were considered nonimmune to rubella. Among the
543 males the susceptibility rate was 13.6% and for the 510
females the corresponding figure was 13.9%. The distribution
of nonimmune by yearly cohort ranged from 3.2% to 25.9%
(data not shown), with an increasing trend in older age groups
(Table 1). Overall, the proportion susceptible reached 19.5%
beyond 12 years of age. The overall proportion susceptible was
significantly higher at 16.5% in the age group eight to 17 years
as opposed to 3.9% for the age group five to eight years of age
(χ2=24.08; df=1, P<0.001). Significant differences in the
proportion of susceptibles were also observed between differ-
ent age groups for both males (χ2=14.94; df=3, P<0.01) and
females (χ2=17.37; df=3, P<0.001). There was a significant
regression of logarithm titre values on the age of the children
with an average decline in titre values of 8.1% per annum.
DISCUSSION
Rubella vaccination was first introduced in Newfoundland
in 1971. The trivalent MMR vaccine introduced in 1974 was
replaced with MMR II vaccine in 1980, and the policy has
remained to give a single dose at 12 months of age. The
current MMR vaccine coverage at school entry in Newfound-
land is over 98%. The most recent outbreaks of rubella in
Newfoundland occurred in 1974 and 1975 and in 1986 and
1987. The 1986 and 1987 outbreak involved over 300 reported
cases and was mostly limited to one health region (19). During
the intervening periods and to date, the number of rubella
notifications in the province had been minimal, ranging from
none to eight per 100,000 population per year (provincial
population 580,000).
Our earlier study of rubella immune status of Newfound-
land children at four to six weeks and six months post-MMR II
vaccination indicated a high rate of seroconversion and pro-
tective immunity to rubella in the range of over 98% (10,20).
In a related study of school-aged children in Quebec, the
proportion immune to rubella still remained quite high, in the
range of 94% to 98% at five to six years post-MMR II vaccina-
tion (9). In a recent study of five-year-old British children, over
99% of vaccinees had protective immunity against rubella at
four years post-MMR II vaccination (21). We also observed
that the presence of afebrile upper respiratory tract infection
at the time of MMR vaccination did not interfere with the
response to the rubella component of the vaccine (22). In the
present cross sectional study, for children up to eight years of
age our result of 96.1% immunity against rubella is only
slightly lower than that of the 98% to 99% immunity levels
cited above for five- to seven-year-old children (9,21). Beyond
eight years of age, however, there is a clear indication of a
sharp decline in the proportion immune (Table 1). In contrast
to this, using the same children population in a related study
dealing with measles vaccine-induced immunity, the level of
protective immunity was found to be lower at 85.7% to start
with at five years of age, and the proportion immune contin-
ued to decline thereafter (23). While the rate of decline in
measles titre levels was 4.6% per annum (23), the correspond-
ing rate of decline for rubella observed in the present study
was 8.1%. At this rate of decline in rubella titre levels, a sizable
proportion of females reaching prime reproductive age is likely
to have no protective immunity against rubella. Our data
showed the overall proportion susceptible reaches close to 20%
beyond 12 years of age among those previously immunized
with a single dose of MMR II vaccine. It is worth noting that in
a recent Swedish study, a steady decline in vaccine-induced
rubella immunity was observed, with the proportion suscepti-
ble reaching 22% at 16 years postvaccination (11). Our obser-
vation in the present study is also substantiated by the data
gathered in Newfoundland through our provincial prenatal
rubella screening program. During the six-year period from
1990 to 1995, women ages 14 to 19 years have accounted for
50% of those testing rubella nonimmune. The proportion sus-
ceptible to rubella in this age group has averaged 15%,
whereas for the screened pregnant women population as a
whole the susceptibility rate averaged 5% (unpublished data).
Our data and those of others (11,12) indicate a declining
level of protection against rubella in previously vaccinated
populations, particularly as the female teenage population
advances into the prime reproductive age group of 20 to 29
years, and thereby needs a second dose of rubella. In this
context, it may be of interest to note that in a separate group
of 45 children, five- to 17-years-old, who were identified dur-
ing this study as having received two doses of MMR II vaccine
and who were studied separately, all had protective immunity
against rubella (unpublished observation). Also, a large scale
TABLE 1
Rubella antibody status in children five to 17 years of age who
received a single dose of MMR II at one year of age
Age group
(years)
Total number
of children
tested
Rubella immune status*
Susceptible (%) Immune (%)
5 to 8 230 9 (3.9) 221 (96.1)
8 to 11 327 46 (14.1) 281 (85.9)
11 to 14 380 66 (17.4) 314 (82.6)
14 to 17 116 24 (20.7) 92 (79.3)
Total 1053 145 (13.8) 908 (86.2)
*Based on a protective cut-off titre of >10 IU. χ2 = 27.67; df= 3;
P<0.001
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study of a two-dose rubella strategy in Sweden found 100%
seroconversion rate after a second dose in a population that
had a susceptibility rate ranging from 41% to 57% after a single
dose (12). However, the longevity of immunity against rubella
following a second dose remains to be studied.
The questions concerning the need for a second dose of
rubella vaccine, the timing of the second dose and occurrence
of waning rubella immunity need to be addressed in the move
to eliminate indigenous rubella infection during pregnancy in
Canada (1). Our study shows that as many as 20% of young
women from 12 to 17 years of age may be entering their
childbearing years susceptible to rubella. Based on our data
and those of others (11,12), it may be concluded that there will
be a greater number of Canadian women susceptible to rubella
in the coming years. This should be of major public health
concern. Obviously, the prenatal screening of women of child-
bearing age will partly alleviate this problem.
A better solution, however, would be a routine two-dose
rubella vaccination strategy. With regard to the timing of the
second dose for rubella, our data suggest that it will be most
beneficial if given after eight years of age. There is consensus
for a routine two-dose measles vaccination strategy in Canada,
and this is being implemented in some provinces (2,17). The
trivalent MMR II vaccine is routinely used for the second dose
in these provinces, and given either at 18 months or at school
entry (17). (Our studies dealing with measles vaccination
strategy has indicated 18 months as the most appropriate age
for a second dose of measles vaccine if the first dose continues
to be given at 12 months of age [24]). Our data clearly support
the use of a bivalent measles-rubella vaccine or trivalent
vaccine such as MMR II rather than a monovalent measles
vaccine for the second dose. However, the impact of the above
timing of the second dose on long term rubella immunity
cannot be predicted at this time. Also, in the above context, the
use of monovalent measles vaccine for ‘catch-up’ programs for
school-aged children (17) may need to be reassessed. Further
studies following a two-dose MMR II vaccination scheduled
either at 18 months or school entry are needed to assess the
impact of this strategy on long term rubella immunity. In the
meantime, our data underscore the need to continue prenatal
rubella screening programs and immunization of those who
are found susceptible.
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